Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Con

Autolus Therapeutics (AUTL) announced updated long-term data from its FELIX study of obecabtagene autoleucel (obe-cel) in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). After a median follow-up of 42.6 months, the median duration of response was 42.6 months, with over half of patients still in remission at 24 months, and 38% of ongoing responders not requiring subsequent therapy by month 33, suggesting obe-cel may be a definitive treatment for a subset of r/r B-ALL patients; no new safety signals were observed. Additional data indicated obe-cel's efficacy and safety profile is consistent across age groups.

Analysis

Autolus Therapeutics (AUTL) has presented compelling updated long-term follow-up data from the FELIX study for obecabtagene autoleucel (obe-cel) in adult relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL), significantly enhancing the product's clinical profile. The median duration of response has now reached an impressive 42.6 months, following an additional 11 months of follow-up, with data indicating that more than half of the patients remained in remission at the 24-month mark. Notably, at a median follow-up of 32.8 months, 38.4% of responders continued in ongoing remission without requiring any subsequent consolidative therapies by month 33, suggesting obe-cel could be a definitive treatment for a considerable portion of these high-risk patients. The 24-month probability of Event Free Survival was 43% and Overall Survival was 46%, with an emerging long-term plateau observed. Critically, no new safety signals or Grade ≥3 secondary malignancies were identified during this extended follow-up, and obe-cel demonstrated consistent efficacy and a positive benefit-risk profile across different age groups, including older adults (≥55 years). The strong positive sentiment (AUTL-specific score of 0.9) and notable market impact score (0.65) reflect the significance of these findings for Autolus, an early commercial-stage biopharmaceutical company, positioning obe-cel as a potentially transformative therapy in the r/r B-ALL landscape.

Key Decisions for Investors

• Investors should recognize that the reported long-term efficacy and safety data for obe-cel substantially strengthens its value proposition and competitive standing in the r/r B-ALL treatment paradigm.
• Given that 38% of ongoing responders did not require subsequent therapy, a key consideration is obe-cel's potential to become a definitive treatment option, which could drive significant market uptake and impact Autolus's revenue trajectory as an early commercial-stage entity.
• Monitor Autolus's presentations at the EHA Congress for further insights and peer discussion, alongside future updates on commercialization progress and market access, particularly as these mature data reinforce obe-cel's clinical differentiation.
• The identification of factors predicting sustained remission, such as lower disease burden and CAR T-cell persistence, may refine patient selection and should be watched for their impact on optimizing clinical outcomes and commercial strategy.